We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 03, 2021

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
J. Clin. Oncol 2021 Feb 01;39(4)273-284, J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, J Desai, F Ciardiello, F Loupakis, YS Hong, N Steeghs, TK Guren, HT Arkenau, P Garcia-Alfonso, E Elez, A Gollerkeri, K Maharry, J Christy-Bittel, S Kopetz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading